Febuxostat for the chronic management of hyperuricemia in patients with gout.

about

Risk of Febuxostat-Associated Myopathy in Patients with CKD.

P2860

Q40288477-E429ED78-8F53-4800-A206-E5A96401EBB6

P2860

Febuxostat for the chronic management of hyperuricemia in patients with gout.

Item

http://www.wikidata.org/entity/Q38760404

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Febuxostat for the chronic management of hyperuricemia in patients with gout.

@en

type

Item

label

Febuxostat for the chronic management of hyperuricemia in patients with gout.

@en

prefLabel

Febuxostat for the chronic management of hyperuricemia in patients with gout.

@en

P1476

Febuxostat for the chronic management of hyperuricemia in patients with gout

@en

P2093

Irati Urionaguena

http://www.w3.org/2001/XMLSchema#string

P2860

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II

A review of uric acid, crystal deposition disease, and gout.

Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.

Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.

Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase.

National prevalence of gout derived from administrative health data in Aotearoa New Zealand.

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.

P304

665-673

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17512433.2016.1162094

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Fernando Perez-Ruiz

Sandra Pamela Chinchilla

P577

2016-03-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26942273

http://www.w3.org/2001/XMLSchema#string

Febuxostat for the chronic management of hyperuricemia in patients with gout.

about

P2860

P2860

Febuxostat for the chronic management of hyperuricemia in patients with gout.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698